Literature DB >> 19506549

Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers.

Hyun Ju Kang1, Hanna Lee, Hee-Jung Choi, Ju Ho Youn, Jeon-Soo Shin, Yeong Hee Ahn, Jong Shin Yoo, Young-Ki Paik, Hoguen Kim.   

Abstract

The high mobility group box 1 (HMGB1) protein, a non-histone nuclear factor, is overexpressed and localizes to the cytoplasm in some cancer cells. However, the mechanism of cytoplasmic HMGB1 transport, extracellular secretion, and its role in cancer progression is not clear. To simulate the activated state of HMGB1, we mutated serine residues of nuclear localization signals (NLSs) to glutamic acid and performed transfection assays. We carried out a kinase inhibitor study and evaluated the cell migration by invasion assay. We showed that phosphorylated HMGB1 localizes in the cytoplasm of colon cancer cells and also showed the interaction of PKC and HMGB1 by immunoprecipitation analysis. Concurrent mutations at six serine residues (35, 39, 42, 46, 53, and 181) to glutamic acid induced the nuclear to cytoplasmic transport of HMGB1, which was detected in the culture medium. We also observed that the secretion of HMGB1 correlated with increased cancer cell invasiveness. Our results suggest that phosphorylated HMGB1 is transported to the cytoplasm, is subsequently secreted from the cell, and has a role in tumor progression through the activation of genes related to cell migration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19506549     DOI: 10.1038/labinvest.2009.47

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  31 in total

1.  Intracellular HMGB1 negatively regulates efferocytosis.

Authors:  Sami Banerjee; Andressa de Freitas; Arnaud Friggeri; Jaroslaw W Zmijewski; Gang Liu; Edward Abraham
Journal:  J Immunol       Date:  2011-09-28       Impact factor: 5.422

2.  Downregulation of high mobility group protein box-1 resensitizes ovarian cancer cells to carboplatin.

Authors:  Wen Shu
Journal:  Oncol Lett       Date:  2018-07-30       Impact factor: 2.967

3.  The effect of PKC phosphorylation on the "architectural" properties of HMGB1 protein.

Authors:  Iva Ugrinova; Stanislava Zlateva; Evdokia Pasheva
Journal:  Mol Biol Rep       Date:  2012-06-28       Impact factor: 2.316

4.  Expression of high mobility group box 1 protein predicts a poorer prognosis for patients with osteosarcoma.

Authors:  Jiliang He; Peng Zhang; Qinghu Li; Dongsheng Zhou; Ping Liu
Journal:  Oncol Lett       Date:  2015-11-10       Impact factor: 2.967

Review 5.  Role of high-mobility group box 1 protein in inflammatory bowel disease.

Authors:  Zhen Hu; Xiaoyun Wang; Lei Gong; Gaojue Wu; Xiaobin Peng; Xuejun Tang
Journal:  Inflamm Res       Date:  2015-06-16       Impact factor: 4.575

6.  The expression of high mobility group box 1 is associated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma.

Authors:  Chen Chuangui; Tang Peng; Yu Zhentao
Journal:  Pathol Oncol Res       Date:  2012-04-29       Impact factor: 3.201

Review 7.  High-mobility group box 1 and cancer.

Authors:  Daolin Tang; Rui Kang; Herbert J Zeh; Michael T Lotze
Journal:  Biochim Biophys Acta       Date:  2010 Jan-Feb

8.  High-sensitivity C-reactive protein and high mobility group box-1 levels in Parkinson's disease.

Authors:  Aslıhan Baran; Mahmut Bulut; Mehmet Cemal Kaya; Özlem Demirpençe; Bünyamin Sevim; Eşref Akıl; Sefer Varol
Journal:  Neurol Sci       Date:  2018-10-23       Impact factor: 3.307

Review 9.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

Review 10.  HMGB1: an overview of its versatile roles in the pathogenesis of colorectal cancer.

Authors:  Kim Jun Cheng; Mohammed Abdullah Alshawsh; Elsa Haniffah Mejia Mohamed; Surendran Thavagnanam; Ajantha Sinniah; Zaridatul Aini Ibrahim
Journal:  Cell Oncol (Dordr)       Date:  2019-11-01       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.